Watch for the first patient enrollment in the HR+/HER2- breast cancer expansion by year-end 2026 and the Phase 2 CRC trial start in Q1 2027. The recent capital raise removes near-term funding risk but adds ~2.3M ADS dilution. Preclinical data alone does not guarantee clinical success, but the breadth of pipeline expansion into large markets (breast, colorectal) is a significant value catalyst for a $157M market cap biotech. Monitor for additional preclinical data presentation later this year.
Price Chart
Executive Summary
Kazia Therapeutics announced preclinical data for paxalisib in two new large-market indications: MSS/pMMR colorectal cancer (tumor burden reduction of 52% as monotherapy, additional 50% reduction with pembrolizumab) and HR+/HER2- breast cancer (resensitization to CDK4/6 inhibitors). The company is expanding its ongoing TNBC trial into HR+/HER2- breast cancer (enrollment start by year-end 2026) and planning a Phase 2 study in MSS/pMMR CRC (start Q1 2027). Recent ~$37M gross capital raise (Aug 31) now funds the program through completion, partially offsetting dilution overhang.
Key Facts
- Paxalisib monotherapy reduced tumor burden by 52% (p=0.035) in MSS/pMMR colorectal cancer model; addition of pembrolizumab drove further 50% reduction (p=0.022).
- Preclinical data in HR+/HER2- breast cancer shows paxalisib resensitized CDK4/6 inhibitor-resistant tumors and showed additive antitumor activity with fulvestrant/palbociclib.
- Kazia is expanding its ongoing TNBC trial into HR+/HER2- breast cancer with a three-arm randomized expansion (paxalisib 15mg + fulvestrant ± palbociclib; paxalisib 30mg + fulvestrant ± palbociclib; standard-of-care). First patient expected by year-end 2026, full enrollment by end of 2027.
- Kazia plans a five-arm Phase 2 trial in MSS/pMMR colorectal cancer (paxalisib monotherapy, paxalisib + pembrolizumab at two dose levels, ± biologic, vs standard-of-care). Enrollment expected Q1 2027, full enrollment by end of 2027.
- New patent filings covering both indications were filed.
- Recent capital raise (Aug 31, 2026, ~$37M net proceeds) provides funding through completion of these programs per management.
- HR+/HER2- breast cancer represents ~60-70% of all breast cancer diagnoses (~322,000 new U.S. cases per year).
- MSS/pMMR colorectal cancer accounts for ~85-90% of metastatic colorectal cancer cases and is unresponsive to checkpoint inhibitor monotherapy.
Financial Impact
Preclinical expansion into two large oncology indications (HR+/HER2- breast cancer and MSS/pMMR CRC) with funded development plan; near-term dilution from recent ~$37M offering at $15.50/ADS (~8.3% discount).
Risk Factors
- Preclinical data may not translate to clinical efficacy in humans.
- Clinical trial enrollment and execution risks — both trials are multi-year with first data readouts not expected until 2027-2028.
- Significant dilution overhang from recent ~$37M offering (2.28M ADS + up to 4.3M additional ADS from warrants).
- Competitive risk from existing PI3K/mTOR inhibitors and other targeted therapies in breast cancer and CRC.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-096263 |
| Document: ea030430701ex99-1.htm | 0001213900-26-096263 |
| Document: ea0304307-6k_kazia.htm | 0001213900-26-096263 |
| Document: 0001213900-26-096263-index-headers.html | 0001213900-26-096263 |
| Document: 0001213900-26-096263-index.html | 0001213900-26-096263 |
| Document: 0001213900-26-096263.txt | 0001213900-26-096263 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $8.09 (−12.73%) |
Sep 22, 2026 5w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $8.09 (−25.92%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $8.09 (−35.84%) |
Aug 31, 2026 8w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $8.09 (+35.95%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $8.09 (−41.25%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.09 (+41.25%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.09 (+41.25%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $8.09 (+40.43%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $8.09 (−40.43%) |
Jul 28, 2026 13w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $8.09 (−36.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers